Clinical Trial of Wax-Matrix Sustained-Release Niacin in a Russian Population with Hypercholesterolemia

Archives of Family Medicine

Volumn 5, Issue 10, 1996, Pages 567-575

  Aronov, David M ^a   Keenan, Joseph M ^b   Akhmedzhanov, Nadir M ^a   Perova, Natalia V ^a   Oganov, Raphael Y ^a   Kiseleva, Natalia Y ^a  

^a NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DRUG VEHICLE; LIPID; NICOTINIC ACID;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; TREATMENT OUTCOME; VEHICLES;

ADULT; AGED; AMBULATORY CARE; CHOLESTEROL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; MOSCOW; NIACIN; TREATMENT OUTCOME; VEHICLES;

EID: 1842558445     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.5.10.567     Document Type: Article

References (38)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558-559.
2. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
3. Blankenhorn DH, Nessim SA, Johnson R, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257: 3233-3240.
4. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
5. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. 1988;148:2493-2495.
6. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
7. Figge HL, Figge J, Souney PF, et al. Comparison of excretion of nicotinuric acid after ingestion of two controlled release nicotinic acid preparations in man. J Clin Pharmacol. 1988;28:1136-1140.
8. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad SM, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high-density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol. 1989;64:725-729.
9. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang Z, Ripsin CM. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424-1432.
10. Keenan JM, Wenz JB, Ripsin CM, Huang Z, McCaffrey DJ. A clinical trial of oat bran and niacin in the treatment of hyperlipidemia. J Fam Pract. 1992;34:313-319.
11. Bucolo G, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem. 1973;5:476-482.
12. Roeschlau P, Berndt E, Gruber W. Enzymatische bestimmung des gezamtcholesterins in serum. Z Klin Chem Klin Biochem. 1974;12:226-229.
13. Assman G, Schkiewer H, Schmitz G, Hagele E. Quantification of high-density lipoprotein cholesterol by precipitation with phosphotungstic acid/MgC12. Clin Chem. 1983;29:2026-2030.
14. Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest. 1972;9:21-37.
15. Curry MD, Alaupovic P, Suenram CA. Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassay. Clin Chem. 1976;22:315-322.
16. Curry MD, Gustavson A, McConathy WJ. Electroimmunoassay evaluated for quantification of human apolipoprotein B. Clin Chem. 1978;24:280-286.
17. Gaubatz JW, Cushing GL, Morrisett JD. Quantitation, isolation and characterization of human lipoprotein (a). Methods Enzymol. 1986;129:167-186.
18. Khaltaev NG, Dennis B. Quantitative evaluation of nutrition in epidemiologic studies of cardiovascular diseases. Kardiologiya (Cardiology). 1976;9:113-118.
19. Anonymous. Chemical Composition of Food Components [in Russian]. Moscow, Russia: Meditsina; 1976.
20. Anonymous. Chemical Composition of Food Components [in Russian]. Moscow, Russia: Meditsina; 1987.
21. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1989.
22. Weiner M, Eys V. Nicotinic Acid: Nutrient-Cofactor-Drug. New York, NY: Marcel Dekker Inc; 1983.
23. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
24. Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids: demonstration of a metabolic type of sympathicolysis. Acta Med Scand. 1962; 172:641-645.
25. Grundy SM, Mok HYI, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981;22:24-36.
26. Carlson LA. Nicotinic acid: its metabolism and its effects on plasma free fatty acids. In: Gey F, Carlson LA, eds. Metabolic Effects of Nicotinic Acid and Its Derivatives. Geneva, Switzerland: Hans Huber Publisher; 1971:157-165.
27. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979;63: 858-867.
28. Wahlberg G, Holmquist L, Walldius G, Annuzzi G. Effects of nicotinic acid on concentrations of serum apolipoproteins B, C-1, C-11, C-111 and E in hyperlipidemic patients. Acta Med Scand. 1988;224:319-327.
29. Spinier SA, Cziraky MJ. Lipoprotein(a): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother. 1994;28:343-351.
30. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-650.
31. Dennis BH, Thomas RP, Irving SH, Furberg B, Zhukovsky GS, Khaltaev NG. Nutrient intake in men aged 20 to 69 years from US and USSR. Lipid Res Clin Popul Atherosclerosis Rev. 1988;17:139-155.
32. Dennis BH, Thomas RP, Irving SH, Furberg B, Deer AD, Khaltaev NG. Nutrient intake in women aged 20 to 69 years from US and USSR. Lipid Res Clin Popul Atherosclerosis Rev. 1988;17:221-242.
33. Khaltaev NG. The association of low- and high-density lipoprotein cholesterol with nutrient intake in men 40 to 59 years old in USSR and US. In: Klimov AN, ed. High Density Lipoprotein Cholesterol and Atherosclerosis. Moscow, Russia: Meditsina; 1983:284-293.
34. Drinka PJ. Alterations in thyroid and hepatic function tests associated with preparations of sustained-release niacin. Mayo Clin Proc. 1992;67:1206
35. Kohn RM, Montes M. Hepatic fibrosis following long acting nicotinic acid therapy: a case report. Am J Med Sci. 1969;258:94-99.
36. Parson WB. Studies of nicotinic acid use in hypercholesteremia: Arch Intern Med. 1961;107:653-667.
37. Coronary Drug Project Research Group. Clobifrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
38. Kreisberg RA. Niacin: a therapeutic dilemma: 'One man's drink is another's poison.' Am J Med. 1994;97:313-316.